On May 9th, the "2025 VBEF Future Healthcare & Pharmaceuticals Top 100 Exhibition," initiated and hosted by the VBData.cn, was grandly held at the Suzhou International Expo Center, where multiple prestigious rankings were unveiled.

Hasten Biopharmaceutical Co., Ltd. (hereinafter referred to as Hasten) was honored to be listed among the "China Top 100 Innovative Pharmaceuticals & Biologics" for its outstanding commercialization advantages, exceptional performance in innovative R&D, and sustained contributions to the industry. Meanwhile, the new third-generation PCSK9 inhibitor, Lerodalcibep (hereinafter referred to as HST101), which is jointly developed by Hasten and LIB Therapeutics, also clinched the "Best Biotechnology Innovative Product".

Mr. Feng Honggang, Chairman and CEO of Hasten, stated: "Hasten is committed to becoming a leading commercial platform and innovation pioneer in the biopharmaceutical industry in the post-centralized procurement era. We adhere to a patient-centric philosophy, leveraging sustainable commercialization capabilities to accelerate the transformation of original research value, deliver innovative treatment solutions, safeguard patient health, and jointly improve lives of people and create social value."

The VBEF rankings were established in 2015. This year, under the theme "THE NOW – The Tipping Point," the Future Healthcare Top 100 list was jointly evaluated and released by industry experts and investment institutions based on the VB100 value assessment model. The rankings aim to discover and recognize China's innovative pioneers who are leading the future trends in healthcare development.